

For Immediate Release

MORGENTHALER APPOINTS BRIDGET RAUVOLA AS INVESTOR RELATIONS PARTNER

Menlo Park, CA. April 21, 2009. Morgenthaler (www.morgenthaler.com), a leading venture capital and private equity firm, today announced the appointment of Bridget Rauvola as investor relations partner. Rauvola will be based in the Boulder, CO. office.

Prior to joining Morgenthaler, Rauvola spent 16 years at Frazier Healthcare Ventures, a leading provider of venture capital and growth equity to emerging healthcare companies. While at Frazier, Rauvola successfully coordinated the fund-raising efforts of four healthcare funds and two technology funds representing over \$1.8 billion in investment capital.

“We are delighted to welcome Bridget to Morgenthaler and to continue our high-caliber investor relations practice established by Spencer Timm,” said Robert “Robin” Bellas, Morgenthaler’s managing partner. “Bridget has excellent relationships with limited partners in our investment areas and has built a national reputation as a consummate professional.”

Rauvola will be replacing Spencer Timm, Morgenthaler’s current investor relations partner, who will be retiring at the end of this year. Timm will continue as a consultant to Morgenthaler on a project basis.

Prior to Frazier Healthcare Ventures, Rauvola was an institutional equity salesperson in the Pacific Northwest Region for Smith Barney Harris Upham (now Citi Smith Barney) and DeanWitter Reynolds (now Morgan Stanley Dean Witter). Prior to the brokerage business, she was a software analyst for Frank Russell. Rauvola earned her M.B.A. from Seattle University and a B.A. in Finance from the University of Montana. She is a member of the NVCA (National Venture Capital Association) Marketing and Communication committee and has presented at several conferences on the topic of investor relations management within a private equity firm.

About Morgenthaler

Morgenthaler is a leading, national venture capital and private equity firm with offices in Boston, MA; Boulder, CO; Cleveland, OH and Menlo Park, CA. It has funded more than 300 companies over 40 years and currently has approximately \$3 billion under management. Morgenthaler has three distinct investment teams: the IT Team, Life Science Team and the Private Equity Team.

The IT Team focuses on venture capital investments in consumer Internet, open mobile, software and clean tech. Recent investments include BlueArc, Brion, Cortina, imeem, JasperSoft, Lending Club, Netli, NexTag, Nominum, Overture Networks, Peregrine Semiconductor, Sezmi, Unity Semiconductors and Voltage Security.

The Life Science Team focuses on venture capital investments in biotechnology and medical devices. Recent investments include: Ardian, Avidia, Cabochon, CardioMind, Catalyst Biosciences, ForSight, IPC The Hospitalist Company, Morphotek, OncoMed Pharmaceuticals, Optiscan, Orexigen, Promedior, Satiety and Vertiflex.

The Private Equity Team focuses on the lower end of the middle market, specifically on industry-leading companies valued from \$25 million to \$250 million. It concentrates its investments in two sectors: high-value manufacturing and business services. Recent investments include: Affinity, Avtron, Comm-Works, Mark Andy, Phillips & Temro, Rotometrics and Ryan Herco Flow Solutions.

Morgenthaler closed MVP IX, a \$400-million venture capital fund, in November of 2008, effectively increasing the fund size for its IT and Life Science Teams by 30% over its previous fund.

###

Media Contact:

Ching Wu

650-388-7620

ching@morgenthaler.com